European generic prescribing trends and biosimilars Posted 29/07/2009
Pressure to control pharmaceutical expenditure and price competition among pharmaceutical companies is fuelling the development of generic medicines markets in ambulatory care in Europe.
Professor Steven Simoens of the Katholieke Universiteit Leuven in Belgium wrote a special report aiming to identify, interpret and discuss the main supply and demand trends affecting the European generic medicines market in ambulatory care. On the supply side, generic price-regulated systems and reference pricing systems are spreading across Europe. On the demand side, European countries have attempted to stimulate demand for generic medicines by focusing on physician prescribing, generic substitution by pharmacists and patient copayments. Finally, the development of biosimilars will probably become an important area of growth for the pharmaceutical industry over the next five years.
Source: Expert Rev Clin Pharmacol. 2008;1(4):497-503.
Comments (0)
Generics News Research General
- Clopidogrel goes off-patent: last of the old-st...Generics/General | Posted 18/05/2012
- Generic atorvastatin could save NHS GBP 350 mil...Generics/News | Posted 18/05/2012
- Can generic competition succeed at reducing cos...Generics/Research | Posted 11/05/2012
- Also noted on generics: 11 May 2012Generics/General | Posted 11/05/2012
Biosimilars News Research General
- Biosimilar filgrastim provides cost savings for...Biosimilars/Research | Posted 11/05/2012
- US Supreme Court looks set to challenge Afforda...Biosimilars/General | Posted 18/05/2012
- Biosimilars approved and marketed in BelgiumBiosimilars/General | Posted 18/05/2012
- Daiichi Sankyo and Coherus BioSciences make bio...Biosimilars/News | Posted 18/05/2012




